C
에스바이오메딕스
304360KOSDAQ의약품 제조업43.5 / 100
Reference Date: 2026-04-13
Financial Score10.0 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 22.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
EsbioMedix is a biotech venture company specializing in the development and production of stem cell therapeutics, leveraging its platform technology to develop innovative drugs for various diseases. Its subsidiary, Estepham, focuses on manufacturing and selling anti-aging cosmetics and medical devices, capitalizing on the growing biopharmaceutical market trends and enhancing competitive advantages through differentiated technologies and products.
Number of Employees
52people
Average Salary
42.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
—Industry Average 1.043.5Point
ROE
-40.30Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
72.79Industry Average 11.980.0Point
6.1x industry avg (risky)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲12.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼22.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -58.4% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (44%)
Current 28,050Won52-week high 40,45052-week low 18,080
1-month return0.0Point
1m -22.73% (strong drop)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
7 totalPositive 0Neutral 7Negative 0
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral사업보고서 (2025.12)2026-03-24
- Neutral감사보고서제출2026-03-23
- Neutral[기재정정]주주총회소집공고2026-03-17
- Neutral[기재정정]의결권대리행사권유참고서류2026-03-17